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Abstract
Background: Alzheimer’s disease (AD) is a complex disorder caused by a combination of genetic and non-genetic
risk factors. In addition, an increasing evidence suggests that epigenetic mechanisms also accompany AD. Genetic
and epigenetic factors are not independent, but multiple loci show genetic-epigenetic interactions, the so-called
quantitative trait loci (QTLs). Recently, we identified the first QTL association with AD, namely Peptidase M20 Domain
Containing 1 (PM20D1). We observed that PM20D1 DNA methylation, RNA expression, and genetic background are
correlated and, in turn, associated with AD. We provided mechanistic insights for these correlations and had shown
that by genetically increasing and decreasing PM20D1 levels, AD-related pathologies were decreased and
accelerated, respectively. However, since the PM20D1 QTL region encompasses also other genes, namely Nuclear
Casein Kinase and Cyclin Dependent Kinase Substrate 1 (NUCKS1); RAB7, member RAS oncogene family-like 1 (RAB7L1);
and Solute Carrier Family 41 Member 1 (SLC41A1), we investigated whether these genes might also contribute to the
described AD association.
Results: Here, we report a comprehensive analysis of these QTL genes using a repertoire of in silico methods as
well as in vivo and in vitro experimental approaches. First, we analyzed publicly available databases to pinpoint the
major QTL correlations. Then, we validated these correlations using a well-characterized set of samples and locus-
specific approaches—i.e., Sanger sequencing for the genotype, cloning/sequencing and pyrosequencing for the
DNA methylation, and allele-specific and real-time PCR for the RNA expression. Finally, we defined the functional
relevance of the observed alterations in the context of AD in vitro. Using this approach, we show that only PM20D1
DNA methylation and expression are significantly correlated with the AD-risk associated background. We find that
the expression of SLC41A1 and PM20D1—but not NUCKS1 and RAB7L1—is increased in mouse models and human
samples of AD, respectively. However, SLC41A1 and PM20D1 are differentially regulated by AD-related stressors, with
only PM20D1 being upregulated by amyloid-β and reactive oxygen species, and with only PM20D1 being
neuroprotective when overexpressed in cell and primary cultures.
Conclusions: Our findings reinforce PM20D1 as the most likely gene responsible of the previously reported PM20D1
QTL association with AD.
Keywords: Alzheimer, mQTL, eQTL, QTL, DNA methylation, RNA expression, PM20D1, SLC41A1, NUCKS1, RAB7L1
Background
Alzheimer’s disease (AD) is the most common neurode-
generative disorder in western societies. It is character-
ized by a progressive decline in mental abilities,
neuronal loss, and the accumulation of two types of pro-
tein aggregates, amyloid plaques and neurofibrillary
tangles [1]. The causes of AD remain elusive, but AD oc-
currence is currently understood as the consequence of
a complex combination of genetic and non-genetic fac-
tors [2], the latter of which are believed to be mediated
by epigenetic mechanisms [3, 4].
The genetic component of AD has been generally in-
terrogated by genome-wide association studies (GWAS),
which have identified an important number of risk loci
associated with AD [5–7], but a causal relationship
thereof remains difficult to establish. In contrast, the epi-
genetic contribution to AD is mainly interrogated by
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locus-specific or epigenome-wide association studies
(EWAS) [8, 9], which have revealed site-specific epigen-
etic alterations and thereby provide mechanistic insights
for a particular risk gene, but often lack the statistical
power of GWAS [10]. Combining both approaches, it is
now possible to identify single nucleotide polymor-
phisms (SNPs) that correlate with alterations in DNA
methylation levels—the so-called methylation quantita-
tive trait loci (mQTLs).
Recently, we reported the first mQTL association
with AD, which converges on the gene Predicted
Metalloproteinase 20D1 (PM20D1) [11]. We have
shown that AD-related cellular stressors—such as the
presence of reactive oxygen species (ROS) and
amyloid-beta (Aβ)—increase PM20D1 expression, that
PM20D1 expression is upregulated in symptomatic
APP/PS1 AD mice and human AD samples, and that
genetic manipulation of PM20D1 levels can modify
the progression of the disease in APP/PS1 mice:
When PM20D1 was overexpressed, disease progres-
sion was delayed; when PM20D1 was decreased, dis-
ease progression was accelerated.
At the same time, two high-throughput studies have
expanded the PM20D1 expression QTL (eQTL) re-
gion, showing that the expression of neighboring
genes to PM20D1 also correlate with several SNPs in
that region, which include Nuclear Casein Kinase
And Cyclin Dependent Kinase Substrate 1 (NUCKS1);
RAB7, member RAS oncogene family-like 1 (RAB7L1);
and Solute Carrier Family 41 Member 1 (SLC41A1),
plus PM20D1 [12, 13]. Therefore, in spite of the re-
ported functional validations for PM20D1 [11], we
cannot completely exclude the possibility that these
genes also contribute to the progression of AD.
In the present study, we combine a series of in silico
methods with in vivo and vitro experiments to provide a
comprehensive analysis of PM20D1 eQTL genes, curated
evidence for an AD association centered on PM20D1,
and further support for the protective role of PM20D1
in AD.
Methods
DNA methylation and genetic background
Hannon et al.’s mQTL database was interrogated for
mQTLs—SNPs and CpGs—in each of the potential
PM20D1 QTL region genes [14]. When significant,
Bonferroni-corrected p values were directly reported.
mQTL SNPs were then investigated in our own post-
mortem human brain cohort of samples from the IDI-
BELL Biobank (Barcelona, Spain). DNA was isolated by
phenol-chloroform extraction from gray matter of 18
control (Braak 0–II; 32% female; age 64 ± 3 years, mean ±
SEM) and 21 Alzheimer’s disease frontal cortex samples
(Braak V–VI; 43% female; age 77 ± 2 years, mean ±
SEM). Genotypes were obtained by Sanger sequencing
using primers listed in Additional file 1: Table S1. DNA
was bisulfite converted using the EZ DNA methylation
kit (Zymo Research), and tested for bisulfite cloning/se-
quencing and pyrosequencing as previously described
[11]. Bisulfite conversion was ensured by including non-
CG cytosines in the dispensation sequence following the
manufacturer’s instructions. Primers for bisulfite clon-
ing/sequencing and pyrosequencing are listed in Add-
itional file 1: Table S1.
RNA expression and genetic background
GTEX [12] and LIBD [13] datasets were investigated for
eQTL correlations in each of the potential PM20D1
QTL region genes. When significant, FDR-corrected p
values were directly reported. Only previously annotated
genes were considered for LIBD prefrontal (PFC) and
hippocampal (Hip) datasets—i.e., Type = “Gene,” Class =
“InEns”; and Type = all, Class = “InGen,” respectively.
eQTL SNPs were then investigated in our cohort of
samples. RNA purification was performed using TRIzol
(Invitrogen), reverse-transcribed using the Thermoscript
RT-PCR system (Invitrogen), and tested using StepOne-
Plus Real-Time PCR System (Applied Biosystems) and
SYBR Green PCR MasterMaster Mix (Applied Biosys-
tems). Three housekeeping genes were used for normal-
izing PCR signals. Primers for real-time PCR are listed
in Additional file 1: Table S1.
The GeneNetwork database (http://www.genenetwork.
org) was also analyzed for the PM20D1 QTL region
genes in the BxD mice population. BxD mice derive
from multiple intercrosses of the C57BL/6 J (B) and
DBA/2 J (D) progenitor mice, later inbred to fix the gen-
erated genetic variation [15]. To date, close to 200 BxD
strains have been generated and extensively character-
ized—at genetic, transcriptomic, and phenotypic levels
(http://www.genenetwork.org/)—which constitutes a
well-established genetic reference for the analysis of
QTLs [16]. The eQTL analysis was performed using the
BxD recombinant inbred (RI) Family group, Liver
mRNA type, EPFL/LISP BXD CD Liver Affy Mouse
Gene 1.0 ST (Apr13) RMA Exon Level dataset, with the
interval mapping for the entire genome [16]. Images
from GeneNetwork Map Viewer are represented.
QTL expression in Alzheimer’s disease
PM20D1 QTL region gene expression was investi-
gated in the aforementioned human brain cohort and
five 12-month-old APP/PSEN1 [17] and five wild-type
littermate male mouse frontal cortex samples. All ani-
mals were maintained under standard animal house
conditions in a 12-h dark-light cycle with free access
to food and water. The experimental procedures were
conducted according to EPFL’s and Switzerland’s
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guidelines on animal welfare (cantonal animal experi-
mentation authorization numbers VD2875.1 and
VD3169).
Functional validation
SH-SY5Y neuroblastoma cells (ATCC) were cultured in
DMEM supplemented with 20% FBS, 100 μ/ml penicillin,
and 100mg/ml streptomycin at 37 °C in a humidified at-
mosphere of 5% CO2. SH-SY5Y cells were treated with
0.2‰ hydrogen peroxide (Merck) and with synthetic
amyloid-β (1–42)-derived diffusible ligands (ADDLs)
(Abcam) during 6 h and 24 h. Cell viability was measured
using Alamarblue cell viability assay (Invitrogen) accord-
ing to the manufacturer’s instructions. Primary hippocam-
pal neuron-glia co-cultures derived from P0 wild-type
mice were cultured in media consisting of Neurobasal
(Invitrogen), B27 supplement (Invitrogen), L-glutamine
(Invitrogen), and penicillin/streptomycin (Invitrogen) (0.2
ml per well) on 96-well plates (2.5 × 104 cells per well)
coated with Cultrex poly-L-lysine (Trevigen). Cells were
infected at DIV6 with 20 × 103 (200 ng/well) viral particles
containing either a GFP (mock) or a PM20D1/SLC41A1
version of the pLVX-IRES-ZsGreen1vector (Promega). At
DIV 14–17, cytotoxicity was assessed using the Cyto-
Tox96 non-radioactive cytotoxicity assay (PROMEGA) ac-
cording to the manufacturer’s instructions.
Statistical analysis
The analyses were performed using Prism 6.0 (GraphPad).
Correlations were calculated using Pearson’s correlation
coefficients, and comparisons using one-way ANOVA
with post hoc Holm-Sidak’s multiple comparison
tests. p values smaller than 0.05 were considered
statistically significant and provided in the figures as fol-
lows: *p < 0.05, **p < 0.01, ***p < 0.005, and ****p < 0.0001.
Results
DNA methylation and genetic background
PM20D1 DNA methylation is strongly correlated with
the rs708727-rs960603 haplotype, and both, methylation
and haplotype, are associated with AD [11] (Fig. 1a). In
particular, multiple CpG sites in the PM20D1 promoter
show strong correlations with rs1172198, rs708727,
rs823082, rs823088, rs1361754, and rs960603 mQTL
SNPs [14] (Table 1). Our previous whole-genome bisul-
fite sequencing (WGBS) analysis discarded similar corre-
lations with PM20D1 neighboring genes [11]. However,
since the eQTL region has been recently expanded in
other tissues, which now also include the genes
NUCKS1, RAB7L1, and SLC41A1 [12, 13] (Table 2), we
cannot completely rule out the possibility that these
genes show similar correlations. In particular, the GTEX
consortium [12] found correlations between these par-
ticular mQTLs and the levels of RNA expression for
NUCKS1, RAB7L1, and SLC41A1 in the cerebellum; for
PM20D1 in the hippocampus; and for NUCKS1,
RAB7L1, SLC41A1, and PM20D1 in other non-brain tis-
sues (e.g., blood, tibial nerve) [12]. In addition, the LIBD
study [13] found correlations for RAB7L1, SLC41A1, and
PM20D1 in the dorsolateral prefrontal cortex, and for
RAB7L1 and PM20D1 in the hippocampus [13]
(Table 2).
Hence, we have expanded our previous analysis and
measured the levels of DNA methylation of these genes
in a genetically well-characterized human cohort of
brain samples by locus-specific bisulfite sequencing and
pyrosequencing (Fig. 1b, c). We observed no significant
correlations between NUCKS1, RAB7L1, and SLC41A1
DNA methylation levels and the genetic background
(Fig. 1b, c). In fact, NUCKS1, RAB7L1, and SLC41A1
promoter regions remained largely unmethylated, inde-
pendently of the genetic background (Fig. 1b). In con-
trast, PM20D1 DNA methylation was strongly correlated
with the genetic background (Fig. 1b, c). Thus, despite
of a previously reported slight correlation for SLC41A1,
i.e., values ranging from 7 to 9% of DNA methylation
[14] (Table 1), PM20D1 arises as the only gene in this
QTL region that truly qualifies as mQTL.
RNA expression and genetic background
Similar to DNA methylation, we analyzed the RNA ex-
pression levels of the PM20D1 QTL genes by allele-
specific and real-time PCR (Fig. 1d, e). NUCKS1,
RAB7L1, and SLC41A1 were found to be expressed from
both chromosomes (Fig. 1d), and showed no significant
correlation with the genetic background, although a
trend for SLC41A1 was observed (Fig. 1e). In contrast,
the expression levels of PM20D1 were significantly cor-
related with the genetic background, and PM20D1 was
mainly expressed from non-methylated chromosomes
(Fig. 1b, c).
To further explore the PM20D1 QTL region, we took
advantage of the BxD mouse population [15], since mice
and humans share a large number of synteny blocks
[18], including the PM20D1 QTL locus. Supporting our
previous results, similar relationships were also observed
in the BxD population, i.e., no effect of the genetic back-
ground for Nucks1, Rab7l1, and Slc41a1, but a strong
correlation for Pm20d1 (Fig. 2). Taken together, these
results suggest that in both, human and mice, the stron-
gest eQTL effect is centered on PM20D1 in the region
under investigation.
QTL expression in Alzheimer’s disease
Genes in close proximity tend to share common regula-
tory elements and to correlate in expression [19, 20].
PM20D1 is upregulated in human and mouse samples of
AD [11], which stipulates that its neighboring genes
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might be dysregulated in similar fashion. Accordingly,
both SLC41A1 and PM20D1 eQTL low expression
carriers seem to be associated with the same AD-risk
haplotype (e.g., rs708727 AA carriers, Table 2 and
Fig. 1e). To account for this possibility, we assessed the
levels of expression of the PM20D1 QTL genes in APP/
PS1 mice and AD human postmortem samples, which
were stratified by the rs708727 genotype. No significant
expression differences were observed for NUCKS1 or
RAB7L1 in the frontal cortex of APP/PS1 mice at symp-
tomatic stages (Fig. 3a), nor in human AD frontal cortex
(Fig. 3b). Conversely, SLC41A1 levels were significantly
increased in both APP/PS1 mice (Fig. 3a) and human
AD samples, together with PM20D1 (Fig. 3b), which
raises the question whether SLC41A1 might have similar
neuroprotective functions as PM20D1 or, alternatively,
whether it participates of AD pathology.
Functional validation
To further disentangle the potential influence of
PM20D1 QTL genes in AD, we next assayed their ex-
pression upon Aβ and ROS exposure, two pathogenic
hallmarks of AD [2]. No significant differences were ob-
served for NUCKS1 or RAB7L1 genes (Fig. 4a, b). Con-
versely, both Aβ and ROS treatments significantly
increased PM20D1 (Fig. 4a, b), while ROS but not Aβ
altered SLC41A1 expression, albeit in opposite direction
(Fig. 4a, b). Of note, the expression of PM20D1 and
SLC41A1 was expected to be positively correlated since
both eQTLs are associated with the same AD-risk haplo-
type—i.e., they share common regulatory elements—and
both genes are increased in mouse and human samples
of AD. However, our results suggest that PM20D1 and
SLC41A1 are regulated by different mechanisms since
only PM20D1 is upregulated by AD-related stressors—
i.e., Aβ and ROS.
Lastly, to investigate whether SLC41A1, alongside with
PM20D1 [11], might also influence AD progression, we
overexpressed both genes in SH-SY5Y cells and primary
neuronal cultures using lentiviral constructs, and assayed
both ROS-induced cell death and cell viability. Confirm-
ing our previous results [11], PM20D1 overexpression
decreased ROS-induced cell death (Fig. 4c) and in-
creased cell viability (Fig. 4d). In contrast, SLC41A1
overexpression did not only not protect against ROS-
induced cell death in SH-SY5Y cells (Fig. 4c), but instead
proved to be detrimental per se (Fig. 4d), which is rem-
iniscent of a previous report in which SLC41A1 overex-
pression was shown to reduce cell survival in multiple
cell lines [21]. Counterintuitively, the AD-risk haplotype
[11] is associated with lower levels of SLC41A1 expres-
sion, together with PM20D1, which seems to indicate
(See figure on previous page.)
Fig. 1 Overview of the full PM20D1 QTL region and its relation to AD in human frontal cortex. a The region comprises several genes (blue
arrows) and is in partial linkage disequilibrium (HapMap CEU recombination map is indicated below the genes). PM20D1 mQTLs are indicated in
black, of which the mQTLs most strongly associated with AD in bold magenta (rs708727) and bold red (rs960603) [11]. b Locus-specific bisulfite
sequencing of PM20D1 QTL region genes. c rs708727 correlations with the levels of DNA methylation of PM20D1 QTL genes in human frontal
cortex measured by pyrosequencing. d rs105692003, rs823144, rs708727, and rs1361754 are located in the coding region of NUCKS1, RAB7L1,
SLC41A1, and PM20D1, respectively, and in linkage disequilibrium. Retrotranscription PCR Sanger sequencing of heterozygous samples detects
RNA transcripts from both chromosomes for all genes, except for PM20D1 in which only one of the chromosomes is active. e rs708727 correlates
with the levels of RNA expression of PM20D1 QTL genes in human frontal cortex measured by qRT-PCR. Single values are represented by dots, p
values from Pearson’s correlations
Table 1 PM20D1 mQTL region genes and SNPs and their DNA methylation correlation obtained from the Hannon database
CpG rs1172198 rs708727 rs823082 rs823088 rs1361754 rs960603 Min Max Delta
NUCKS1 - - - - - - - - - -
RAB7L1 - - - - - - - - - -
SLC41A1 cg23034840 - 7.60E−08 - 2.90E−05 - - 7 9 2
PM20D1 cg07157834 - 3.60E−22 - - - - 83 90 7
PM20D1 cg24503407 4.60E−08 1.90E−25 7.20E−16 - 7.20E−16 1.80E−12 60 87 27
PM20D1 cg07167872 2.80E−07 5.00E−26 7.00E−16 4.10E−10 6.90E−16 1.90E−13 41 79 38
PM20D1 cg11965913 2.30E−11 2.30E−37 2.50E−19 1.50E−10 2.50E−19 1.30E−14 15 75 60
PM20D1 cg14893161 1.30E−12 4.30E−34 7.00E−19 1.30E−09 7.00E−19 1.40E−13 17 70 53
PM20D1 cg14159672 1.30E−08 3.00E−30 3.20E−18 1.20E−10 3.20E−18 3.10E−13 22 87 65
PM20D1 cg26354017 1.40E−09 5.60E−33 2.10E−18 4.50E−10 2.10E−18 1.10E−14 12 83 71
PM20D1 cg17178900 7.00E−08 1.20E−19 1.20E−13 - 1.20E−13 4.10E−09 40 87 47
Values represent CpG DNA methylation and SNP correlation Bonferroni-corrected p values from Hannon et al. [14], n = 166 prefrontal cortex samples (https://
epigenetics.essex.ac.uk/mQTL/). Min lowest value, Max highest value, Delta highest − lowest values. Significantly differentially probes for each gene are
represented. “-,” not significant
Sanchez-Mut et al. Clinical Epigenetics           (2020) 12:20 Page 5 of 11
Ta
b
le
2
PM
20
D
1
m
Q
TL
re
gi
on
ge
ne
s
an
d
SN
Ps
an
d
th
ei
r
RN
A
ex
pr
es
si
on
co
rr
el
at
io
ns
fro
m
G
TE
X
an
d
LI
BD
da
ta
ba
se
s
an
d
ou
r
ow
n
co
ho
rt
rs
11
72
19
8
rs
70
87
27
G
TE
X
H
ip
G
TE
X
C
B
G
TE
X
TN
LI
BD
PF
C
LI
BD
H
ip
FC
X
G
TE
X
H
ip
G
TE
X
C
B
G
TE
X
TN
LI
BD
PF
C
LI
BD
H
ip
FC
X
N
U
C
KS
1
n.
s.
n.
s.
3.
30
E−
12
n.
s.
n.
s.
n.
s.
n.
s.
1.
80
E−
05
1.
00
E−
11
n.
s.
n.
s.
n.
s.
RA
B7
L1
n.
s.
4.
00
E−
08
1.
50
E−
12
n.
s.
5.
20
E−
06
n.
s.
n.
s.
8.
20
E−
07
7.
80
E−
13
n.
s.
4.
40
E−
03
n.
s.
SL
C
41
A
1
n.
s.
3.
60
E−
06
5.
00
E−
08
n.
s.
n.
s.
n.
s.
n.
s.
2.
00
E−
06
3.
20
E−
10
n.
s.
n.
s.
n.
s.
PM
20
D
1
1.
40
E−
07
n.
s.
1.
90
E−
36
2.
04
E−
7
1.
34
E−
03
0.
01
85
2.
40
E−
13
n.
s.
1.
60
E−
66
4.
73
E−
14
3.
83
E−
07
2.
83
E−
07
rs
82
30
82
rs
82
30
88
G
TE
X
H
ip
G
TE
X
C
B
G
TE
X
TN
LI
BD
PF
C
LI
BD
H
ip
FC
X
G
TE
X
H
ip
G
TE
X
C
B
G
TE
X
TN
LI
BD
PF
C
LI
BD
H
ip
FC
X
N
U
C
KS
1
n.
s.
n.
s.
n.
s.
n.
s.
n.
s.
n.
s.
n.
s.
n.
s.
n.
s.
n.
s.
n.
s.
n.
s.
RA
B7
L1
n.
s.
n.
s.
4.
30
E−
10
3.
37
E−
04
6.
71
E−
07
n.
s.
n.
s.
n.
s.
n.
s.
8.
25
E−
04
2.
75
E−
05
n.
s.
SL
C
41
A
1
n.
s.
n.
s.
7.
40
E−
09
5.
55
E−
03
n.
s.
n.
s.
n.
s.
n.
s.
n.
s.
4.
32
E−
04
n.
s.
n.
s.
PM
20
D
1
3.
20
E −
09
n.
s.
1.
40
E−
29
9.
97
E−
06
0.
02
51
5
3.
10
E−
4
n.
s.
n.
s.
3.
20
E−
16
0.
00
27
9
n.
s.
4.
94
E−
04
rs
13
61
75
4
rs
96
06
03
G
TE
X
H
ip
G
TE
X
C
B
G
TE
X
TN
LI
BD
PF
C
LI
BD
H
ip
FC
X
G
TE
X
H
ip
G
TE
X
C
B
G
TE
X
TN
LI
BD
PF
C
LI
BD
H
ip
FC
X
N
U
C
KS
1
n.
s.
n.
s.
n.
s.
n.
s.
n.
s.
n.
s.
n.
s.
n.
s.
7.
60
E−
06
n.
s.
n.
s.
n.
s.
RA
B7
L1
n.
s.
n.
s.
4.
30
E−
10
2.
61
E−
04
1.
12
E−
06
n.
s.
n.
s.
n.
s.
4.
60
E−
06
n.
s.
1.
53
E−
03
n.
s.
SL
C
41
A
1
n.
s.
n.
s.
7.
40
E−
09
n.
s.
n.
s.
0.
04
77
n.
s.
n.
s.
n.
s.
n.
s.
n.
s.
n.
s.
PM
20
D
1
3.
20
E−
09
n.
s.
1.
40
E−
29
2.
18
E−
05
0.
02
88
7
4.
85
E−
06
n.
s.
n.
s.
3.
00
E−
29
6.
25
E−
06
4.
80
E−
05
0.
03
67
Va
lu
es
in
G
TE
X
an
d
LI
BD
co
lu
m
ns
re
pr
es
en
t
ge
ne
ex
pr
es
si
on
an
d
SN
P
co
rr
el
at
io
n
FD
R-
co
rr
ec
te
d
p
va
lu
es
fr
om
G
TE
X
[1
2]
(h
tt
ps
://
w
w
w
.g
te
xp
or
ta
l.o
rg
)
an
d
LI
BD
(h
tt
p:
//
eq
tl.
br
ai
n
se
q.
or
g)
[1
3]
da
ta
se
ts
.G
TE
X,
hi
pp
oc
am
pu
s
(H
ip
)
n
=
11
1,
ce
re
be
llu
m
(C
B)
n
=
15
4,
tib
ia
ln
er
ve
(T
N
)
n
=
36
1;
LI
BD
,d
or
so
la
te
ra
lp
re
fr
on
ta
lc
or
te
x
(P
FC
)
n
=
41
2,
hi
pp
oc
am
pu
s
(H
ip
)
n
=
39
4.
In
ita
lic
s,
co
rr
el
at
io
n
p
va
lu
es
ob
ta
in
ed
fr
om
ou
r
co
ho
rt
of
fr
on
ta
lc
or
te
x
sa
m
pl
es
(F
CX
)
n
=
39
.n
.s
.n
ot
si
gn
ifi
ca
nt
Sanchez-Mut et al. Clinical Epigenetics           (2020) 12:20 Page 6 of 11
Fig. 2 eQTL analysis overview of BxD mouse cohort extracted from the GeneNetwork database. The PM20D1 QTL region is located on
chromosome 1, where the sequence site is indicated (in purple). Top correlated SNPs are indicated in gray. Top values represent chromosomes.
Left values represent likelihood ratio statistics (LRS), blue line. Thresholds for suggestive and significant LRS are indicated in gray and red,
respectively. Right values represent additive coefficients (AC), green and red lines for C57BL/6 J (B) and DBA/2 J (D) alleles, respectively
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that the epigenetic association with AD and the upregu-
lation of SLC41A1 in AD are the consequence of differ-
ent mechanisms.
In sum, these lines of evidence corroborate our previous
results on PM20D1 and suggest that PM20D1—which is
upregulated and protective in response to AD-related
stressors—is the main gene responsible of the AD-risk
haplotype, while the evidence for SLC41A1 is less consist-
ent and in a different direction.
Discussion
Our previous study has identified PM20D1 as a risk fac-
tor for AD [11]. We found that PM20D1 DNA methyla-
tion and RNA expression were correlated with the
genetic background, which, in turn, was associated with
AD. Moreover, we demonstrated that by genetically in-
creasing and decreasing PM20D1 expression, AD-related
pathologies were decreased and increased, respectively.
Recently, the PM20D1 QTL region has been expanded
to other genes, including NUCKS1, RAB7L1, and
SLC41A1 genes [12, 13] (data shown in Table 2). These
genes are in partial linkage disequilibrium with PM20D1
and, thereby, potentially contribute to our AD-
associated risk haplotype.
In order to test this hypothesis, we have performed a
comprehensive analysis of PM20D1 QTL genes, at the
DNA methylation, RNA expression, and functional level,
using APP/PS1, human postmortem AD samples, as well
as mouse in vivo and in vitro experiments. We found no
significant correlations between the genetic background
and the DNA methylation and/or RNA expression levels
of other PM20D1 QTL genes, except for the previously
reported PM20D1 itself (Fig. 1b–e, Fig. 2, Tables 1 and
2). This is in contrast to other studies, which, in addition
to PM20D1, reported significant RNA expression corre-
lations with the genetic background for NUCKS1,
RAB7L1, and SLC41A1 (Table 2) [12, 13]. However, the
strongest effects were found for rs708727 and PM20D1
DNA methylation, and for rs708727 and PM20D1 RNA
expression in all datasets containing PM20D1, which
pinpoints PM20D1 as the major QTL in the region (Ta-
bles 1 and 2). The reported discrepancies between these
studies could lie in the power of the analysis, since the
GTEX and LIBD studies contain bigger cohorts; differ-
ent methods used, i.e., locus-specific versus the high-
throughput approaches; and tissue- or brain region-
specific eQTL effects, for example, PM20D1 is not found
in the cerebellum GTEX dataset. Consequently, whether
PM20D1 is cell-type and/or tissue-specifically regulated
will surely be a matter of future investigations.
Between control and AD samples, we observed no sig-
nificant differences between the levels of RNA expres-
sion of PM20D1 QTL genes either, except for the
previously reported PM20D1 and the newly reported
SLC41A1, which were both increased in mouse and hu-
man samples of AD (Fig. 3a, b). However, AD-related
stressors such as Aβ and ROS exclusively upregulated
PM20D1 expression, but not SLC41A1, which was either
not affected or downregulated, respectively. In line with
these results, only PM20D1 overexpression was found to
protect against ROS-mediated cytotoxicity (Fig. 4c) and
to increase cell viability (Fig. 4d), whereas SLC41A1
overexpression was either not protective (Fig. 4c) or
even detrimental (Fig. 4d). These results are in concord-
ance with other previous investigations. PM20D1 over-
expression and depletion have been shown to be well
tolerated [22, 23]. Both adeno-associated virus trans-
duced [22] and PM20D1 knockdown [23] mice are vi-
able and appear healthy, although these manipulations
led to altered N-acyl amino acid production, which af-
fects thermogenesis regulation [22, 23]. On the contrary,
both the overexpression and the depletion of SLC41A1
have been found to be detrimental. SLC41A1 overex-
pression reduced cell survival in multiple cell lines [21],
while morpholino-mediated depletion induced severe
developmental abnormalities in zebrafish [24], which
Fig. 3 Expression of PM20D1 QTL genes in AD. a Expression of PM20D1 QTL genes in human AD samples stratified by genotype. b Expression of
PM20D1 QTL genes in APP/PS1 frontal cortex samples. Data are presented as means ± SEM. *p < 0.05; **p < 0.01; one-way ANOVA, post hoc Holm-
Sidak’s multiple comparison test
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suggests the need of well-controlled levels of SLC41A1.
Interestingly, both PM20D1 and SLC41A1 are expressed
by astrocytes [25] and might therefore be indirectly asso-
ciated with increased levels of gliosis in AD [17, 26].
However, as the lack of expression of both PM20D1 and
SLC41A1 is associated with a higher risk of AD, but only
PM20D1 is upregulated by AD-related stressors and
neuroprotective, this suggests that first, PM20D1 is the
most relevant gene for AD within the analyzed loci, and
second, that the increased levels of SLC41A1 in AD
might be a mere consequence of the increased number
of astrocytes.
Interestingly, PM20D1 has previously been shown
to activate mitochondrial uncoupling [22], which pro-
motes neuronal survival [27] and appears to be pro-
tective against neurodegenerative disorders including
AD and Parkinson’s disease (PD) [28]. Mitochondrial
uncoupling plays important roles in the adaptive re-
sponses to bioenergetic and oxidative stressors. It de-
creases ROS production, prevents mitochondrial
calcium accumulation, and regulates protein and sub-
strate mitochondrial import [29]. In addition,
PM20D1 itself has also been related to several disor-
ders characterized by high levels of ROS, such as dia-
betes [22] and obesity [22], and to neurodegenerative
diseases with strong mitochondrial alterations, includ-
ing multiple sclerosis [30] and PD [31]. Taken to-
gether, these data suggest a potential use of PM20D1-
derived treatment approaches not only for AD, but
likely also other diseases.
In sum, our results further support that PM20D1 is
the most likely responsible candidate of the previously
reported QTL association with AD, and reinforce its
protective role in AD. How precisely PM20D1 exerts its
protective functions now requires further investigations.
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